Design of the VIALE-M phase III trial of venetoclax and oral azacitidine maintenance therapy in acute myeloid leukemia

被引：20

作者：

Ivanov, Vladimir ^{[1
]}

Yeh, Su-Peng ^{[2
]}

Mayer, Jiri ^{[3
,4
]}

Saini, Lalit ^{[5
]}

Unal, Ali ^{[6
]}

Boyiadzis, Michael ^{[7
]}

Hoffman, David M. ^{[8
]}

Kang, Kingston ^{[8
]}

Addo, Sadiya N. ^{[8
]}

Mendes, Wellington L. ^{[8
]}

Fathi, Amir T. ^{[9
]}

机构：

[1] Almazov Natl Med Res Ctr, St Petersburg, Russia

[2] China Med Univ Hosp, Taichung, Taiwan

[3] Fak Nemocnice Brno, Brno, Czech Republic

[4] Masaryk Univ, Brno, Czech Republic

[5] London Hlth Sci Ctr, London, ON, Canada

[6] Erciyes Univ, Sch Med, Kayseri, Turkey

[7] Genentech Inc, San Francisco, CA USA

[8] AbbVie Inc, N Chicago, IL USA

[9] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02115 USA

来源：

FUTURE ONCOLOGY | 2022年 / 18卷 / 26期

关键词：

acute myeloid leukemia; BCL-2; inhibitor; CC-486 (oral azacitidine); first remission; maintenance therapy; minimal residual disease conversion; phase III; relapse-free survival; venetoclax; QUALITY-OF-LIFE; HEMATOPOIETIC-CELL TRANSPLANTATION; CONVENTIONAL CARE REGIMENS; LOW-DOSE CYTARABINE; OLDER PATIENTS; COMPLETE REMISSION; ELDERLY-PATIENTS; POSTREMISSION TREATMENT; TREATMENT OUTCOMES; BCL-2; INHIBITION;

D O I：

10.2217/fon-2022-0450

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Prevention of relapse is a major therapeutic challenge and an unmet need for patients with acute myeloid leukemia (AML). Venetoclax is a highly selective, potent, oral BCL-2 inhibitor that induces apoptosis in AML cells. When combined with azacitidine, it leads to prolonged overall survival and rapid, durable remissions in treatment-naive AML patients ineligible for intensive chemotherapy. VIALE-M is a randomized, double-blind, two-arm study to evaluate the safety and efficacy of venetoclax in combination with oral azacitidine (CC-486) as maintenance therapy in patients in complete remission with incomplete blood count recovery after intensive induction and consolidation therapies. The primary end point is relapse-free survival. Secondary outcomes include overall survival, minimal residual disease conversion and improvement in quality-of-life.

引用

页码：2879 / 2889

页数：11

共 50 条

[31] Trial in Progress: Phase Ib/II Study of Siremadlin in Combination With Venetoclax plus Azacitidine in Patients With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy (IC) [J].

Daver, Naval G. ;

Wei, Andrew H. ;

Stein, Eytan M. ;

DeAngelo, Daniel J. ;

Pathak, Dhrubajyoti ;

Xu, Yunnan ;

Grzesiak, Stephanie ;

Venditti, Adriano .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 :S217-S217

[32] Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial [J].

Ravandi, Farhad ;

Roboz, Gail J. ;

Wei, Andrew H. ;

Dohner, Hartmut ;

Pocock, Christopher ;

Selleslag, Dominik ;

Montesinos, Pau ;

Sayar, Hamid ;

Musso, Maurizio ;

Figuera-Alvarez, Angela ;

Safah, Hana ;

Tse, William ;

Sohn, Sang Kyun ;

Hiwase, Devendra ;

Chevassut, Timothy ;

Pierdomenico, Francesca ;

La Torre, Ignazia ;

Skikne, Barry ;

Bailey, Rochelle ;

Zhong, Jianhua ;

Beach, C. L. ;

Dombret, Herve .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)

[33] A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations [J].

Desikan, Sai Prasad ;

Ravandi, Farhad ;

Pemmaraju, Naveen ;

Konopleva, Marina ;

Loghavi, Sanam ;

Jabbour, Elias J. ;

Daver, Naval ;

Jain, Nitin ;

Chien, Kelly S. ;

Maiti, Abhishek ;

Montalban-Bravo, Guillermo ;

Kadia, Tapan M. ;

Macaron, Walid ;

DeLumpa, Ricardo ;

Kwari, Monica ;

Borthakur, Gautam ;

Short, Nicholas J. .

ACTA HAEMATOLOGICA, 2022, 145 (05) :529-536

[34] Low-dose azacitidine maintenance therapy after allogeneic stem cell transplantation for high-risk pediatric acute myeloid leukemia [J].

Tamura, Akihiro ;

Ishida, Toshiaki ;

Saito, Atsuro ;

Yamamoto, Nobuyuki ;

Yokoi, Takehito ;

Uemura, Suguru ;

Nino, Nanako ;

Fujiwara, Takahiro ;

Tahara, Teppei ;

Nakamura, Sayaka ;

Kozaki, Aiko ;

Kishimoto, Kenji ;

Hasegawa, Daiichiro ;

Kosaka, Yoshiyuki .

PEDIATRIC BLOOD & CANCER, 2018, 65 (10)

[35] Maintenance Therapy with Combination of Azacitidine, Danazol and Thalidomide after Intensive Chemotherapy in Acute Myeloid Leukemia Patients [J].

Zheng, Fang ;

Li, Qianqian ;

Yang, Sisi ;

Zhou, Zhen ;

Zeng, Qingfan ;

Mi, Yingchang ;

Liu, Kaiqi .

BLOOD, 2022, 140 :11720-11722

[36] Real-world tolerability of venetoclax-based maintenance therapy with azole antifungal prophylaxis for acute myeloid leukemia in remission [J].

Nguyen, Phillip C. ;

Donati, Vanessa ;

Vassili, Catherine ;

Grigg, Andrew P. ;

Tiong, Ing S. .

LEUKEMIA RESEARCH, 2022, 116

[37] A Phase I/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid Leukemia [J].

Medeiros, Bruno C. ;

Tanaka, Tiffany N. ;

Balaian, Larisa ;

Bashey, Asad ;

Guzdar, Amy ;

Li, Hongying ;

Messer, Karen ;

Ball, Edward D. .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (05) :346-+

[38] A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia [J].

Vives, Susana ;

Martinez-Cuadron, David ;

Bergua Burgues, Juan ;

Algarra, Lorenzo ;

Tormo, Mar ;

Martinez-Sanchez, Maria Pilar ;

Serrano, Josefina ;

Herrera, Pilar ;

Ramos, Fernando ;

Salamero, Olga ;

Lavilla, Esperanza ;

Lopez-Lorenzo, Jose L. ;

Gil, Cristina ;

Vidriales, Belen ;

Falantes, Jose F. ;

Serrano, Alfons ;

Labrador, Jorge ;

Sayas, Maria J. ;

Foncillas, Maria A. ;

Amador Barciela, Maria L. ;

Olave, Maria Teresa ;

Colorado, Mercedes ;

Gascon, Adriana ;

Fernandez, Maria a. ;

Simiele, Adriana ;

Perez-Encinas, Manuel M. ;

Rodriguez-Veiga, Rebeca ;

Garcia, Olga ;

Martinez-Lopez, Joaquin ;

Barragan, Eva ;

Paiva, Bruno ;

Sanz, Miguel A. ;

Montesinos, Pau .

CANCER, 2021, 127 (12) :2003-2014

[39] Real-world effectiveness of first-line azacitidine or decitabine with or without venetoclax in acute myeloid leukemia patients unfit for intensive therapy [J].

Acker, Fabian ;

Chromik, Joerg ;

Tiedjen, Emily ;

Wolf, Sebastian ;

Vischedyk, Jonas B. ;

Makowka, Philipp ;

Enssle, Julius C. ;

Kouidri, Khouloud ;

Sebastian, Martin ;

Steffen, Bjoern ;

Oellerich, Thomas ;

Serve, Hubert ;

Neubauer, Andreas ;

Schaefer, Jonas A. ;

Bittenbring, Joerg T. .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 113 (05) :623-630

[40] Efficacy of tosedostat a novel, oral agent for elderly patients with relapsed or refractory acute myeloid leukemia: a review of the Phase II OPAL trial [J].

Mathisen, Michael S. ;

Ravandi, Farhad .

FUTURE ONCOLOGY, 2012, 8 (04) :351-357

← 1 2 3 4 5 →